Loading asset research
SAB Biotherapeutics Inc. Common Stock
SABSNasdaq · USD · StocksQuote as of · Exchange session not verified$3.41
-0.29%
Today
SABS
Loading 1D prices…
Market cap
$310.3M
Volume
712K
52w high
$5.1552w low
$1.85Company profile
SAB Biotherapeutics Inc. Common Stock
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Miami Beach, FL, United States
Employees
86
Fiscal year end
1231
CIK
1833214
Session & valuation
Open$3.45
Previous close$3.42
Day high$3.54
Day low$3.38
30-day avg. volume349K
Outstanding shares91M
Diluted EPS-$0.79
Latest annual period
P/E (trailing)14.21
P/E (forward)-3.57
Price / book1.33
Beta0.54
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| CLLSCellectis S.A. American Depositary Shares | $312.2M | $72.9M | -92.66% | -$0.67 | -0.64% | Buy |
| AGENAgenus Inc. Common Stock | $312.4M | $114.2M | -2.70% | $0.00 | +0.58% | Buy |
| IKTInhibikase Therapeutics Inc. Common Stock | $326.5M | $0.00 | — | -$0.49 | +0.43% | Buy |
| STROSutro Biopharma Inc. Common Stock | $279.6M | $102.5M | -186.37% | -$22.49 | -5.44% | Buy |
| OCGNOcugen Inc. Common Stock | $345.9M | $4.4M | -1540.90% | -$0.23 | +0.00% | Buy |